Commodore Capital LP Has $80.68 Million Stake in Xenon Pharmaceuticals Inc. $XENE

Commodore Capital LP lowered its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 33.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,800,000 shares of the biopharmaceutical company’s stock after selling 900,000 shares during the quarter. Xenon Pharmaceuticals accounts for about 5.4% of Commodore Capital LP’s holdings, making the stock its 4th largest position. Commodore Capital LP’s holdings in Xenon Pharmaceuticals were worth $80,676,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of XENE. Holocene Advisors LP bought a new stake in shares of Xenon Pharmaceuticals in the 2nd quarter worth approximately $56,637,000. Wellington Management Group LLP lifted its position in shares of Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after acquiring an additional 1,435,096 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Xenon Pharmaceuticals by 1,968.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company’s stock worth $38,650,000 after acquiring an additional 820,608 shares during the period. Vestal Point Capital LP lifted its position in shares of Xenon Pharmaceuticals by 53.8% during the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $62,600,000 after buying an additional 700,000 shares during the period. Finally, Barclays PLC lifted its position in shares of Xenon Pharmaceuticals by 439.9% during the 4th quarter. Barclays PLC now owns 600,964 shares of the biopharmaceutical company’s stock worth $26,935,000 after buying an additional 489,664 shares during the period. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Xenon Pharmaceuticals stock opened at $53.20 on Thursday. The company has a market capitalization of $5.14 billion, a PE ratio of -11.32 and a beta of 0.62. Xenon Pharmaceuticals Inc. has a one year low of $30.00 and a one year high of $63.95. The business has a 50 day simple moving average of $55.16 and a 200 day simple moving average of $49.17.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.17). During the same period in the prior year, the company posted ($0.83) earnings per share. Equities analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the transaction, the director owned 24,896 shares in the company, valued at approximately $1,322,973.44. The trade was a 5.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the transaction, the director owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. The trade was a 44.99% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 4.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on XENE shares. Guggenheim restated a “buy” rating and set a $90.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. JPMorgan Chase & Co. raised their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Wednesday, April 8th. Morgan Stanley set a $97.00 target price on Xenon Pharmaceuticals in a research report on Monday, March 9th. Finally, Robert W. Baird raised their target price on Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an “outperform” rating in a research report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $77.20.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.